Third Harmonic Bio
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 30
- Market Cap
- $507.5M
- Website
- http://thirdharmonicbio.com
- Introduction
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
A First in Human Trial Evaluating THB335 in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy
- Interventions
- Drug: THB335 single doseDrug: THB335 fasted/fedDrug: THB335 multiple doseDrug: Single dose placeboDrug: Placebo fasted/fedDrug: Multiple dose placebo
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Third Harmonic Bio, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06425861
- Locations
- 🇺🇸
QPS Miami, Miami, Florida, United States
A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria
Phase 1
Terminated
- Conditions
- Chronic Cold Urticaria
- Interventions
- Drug: THB001
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Third Harmonic Bio, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05510843
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
🇩🇪Charité - Universitätsmedizin Berlin Institute of Allergology, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath